• 1
    Motheral B, Brooks J, Clark MA, et al. A checklist for retrospective database studies—report of the ISPOR task force on retrospective databases. Value Health 2003;6:907.
  • 2
    Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001;134:66394.
  • 3
    Pitkin RM, Branagan MA, Burmeister LF. Accuracy of data in abstracts of published research articles. JAMA 1999;281:111011.
  • 4
    Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care 1998;26:81423.
  • 5
    Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 1999;21:107490.
  • 6
    Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;50:10516.
  • 7
    Morningstar BA, Sketris IS, Kephart GC, Sclar DA. Variation in pharmacy prescription refill adherence measures by type of oral antihyperglycaemic drug therapy in seniors in Nova Scotia, Canada. J Clin Pharm Ther 2002;27:21320.
  • 8
    Dezii CM. Persistence with drug therapy: a practical approach using administrative claims data. Manag Care 2001;10:425.
  • 9
    Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288:4556.
  • 10
    Benner JS, Pollack MF, Smith TW, et al. Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy. Am J Health Syst Pharm 2005;62:146875.
  • 11
    Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005;165:114752.
  • 12
    Benner JS, Tierce JC, Ballantyne CM, et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics 2004;22(Suppl. 3):1323.
  • 13
    Mauskopf JA, Paramore C, Lee WC, Snyder EH. Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings. J Manag Care Pharm 2005;11:23151.
  • 14
    Cramer JA, Sernyak M. Treatment options: switching atypical antipsychotic drugs or augmentation with divalproex, a naturalistic study. Clin Ther 2004; 26:90514.
  • 15
    Cramer JA, Pugh MJ. The influence of insulin usage on glycemic control: how well do adults follow prescriptions for insulin? Diabetes Care 2005;28:7883.
  • 16
    Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:2130.
  • 17
    Levine M, Ensom MH. Post hoc power analysis: an idea whose time has passed? Pharmacotherapy 2001;21:4059.
  • 18
    Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127(8 Pt 2):75763.
  • 19
    Charlson ME, Pompei P, Ales KL, McKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:37383.
  • 20
    McGregor JC, Kim PW, Perencevich EN, et al. Utility of the Chronic Disease Score and Charlson Comorbidity Index as comorbidity measures for use in epidemiologic studies of antibiotic-resistant organisms. Am J Epidemiology 2005;161:48393.
  • 21
    Skelton JR, Edwards SJ. The function of the discussion section in academic medical writing. BMJ 2000;320:126970.
  • 22
    Docherty M, Smith R. The case for structuring the discussion of scientific papers. BMJ 1999;318:12245.
  • 23
    Alpert JS, Furman S, Smaha L. Conflicts of interest: science, money, health. Arch Intern Med 2002;162:6357.
  • 24
    Hasegawa GR. Full disclosure. Am J Health-Sys Pharm 2002;59:1835.